

		FHCRC	SUJC	MICH	T/CL/B 2016	TCGA	TCGA 2015	B/C 2013	MSKCC 2010	B/C 2012	MSKCC 2014	Total	% of Total	Total per group
	# Patients	176	150	61	114	332	333	57	103	112	104			
	# Available	60	150	59	77	332	333	57	103	112	104	1387		
Steroid	AR	40	95	31	43	4	4	1	10	0	0	228	16.44	387.00
	ESR1	5	4	1	8	1	1	1	0	0	0	21	1.51	
	ESR2	4	2	0	12	3	3	1	1	0	0	26	1.87	
	NR2C1	3	1	2	17	4	4	1	1	0	0	33	2.38	
	NR2C2	2	4	0	21	3	3	0	0	2	0	35	2.52	
	PGR	4	3	3	16	7	7	3	0	1	0	44	3.17	
Other Liganded	HNF4A	0	2	1	18	4	4	0	0	0	0	29	2.09	472.00
	HNF4G	18	24	16	41	20	20	5	5	0	2	151	10.89	
	RARA	2	2	2	19	2	2	0	0	4	0	33	2.38	
	RARB	1	3	0	21	5	5	3	0	1	0	39	2.81	
	RARG	3	0	0	13	4	4	0	0	0	0	24	1.73	
	RXRA	1	1	2	18	5	5	1	0	1	0	34	2.45	
	RXRB	2	1	1	14	1	1	2	1	0	0	23	1.66	
	RXRG	4	2	0	21	9	9	0	0	0	0	45	3.24	
	THRA	4	3	1	18	3	3	0	0	0	0	32	2.31	
	THRB	1	3	0	21	6	6	0	0	1	0	38	2.74	
VDR	2	0	0	15	3	3	0	1	0	0	24	1.73		
Metabolic	NR1H2	6	0	1	17	3	3	1	0	0	0	31	2.24	235.00
	NR1H3	3	1	1	15	10	10	1	0	0	0	41	2.96	
	NR1H4	3	3	3	18	7	7	1	1	0	0	43	3.10	
	NR1I2	2	4	3	18	5	5	1	0	0	0	38	2.74	
	PPARA	2	2	3	5	5	5	1	1	0	0	24	1.73	
	PPARD	0	2	1	13	3	3	1	0	0	0	23	1.66	
	PPARG	3	1	0	21	5	5	0	0	0	0	35	2.52	
Orphan	NR0B1	10	6	8	27	6	6	0	0	0	0	63	4.54	836.00
	NR0B2	3	0	0	7	2	2	0	0	0	0	14	1.01	
	NR2E1	4	7	3	8	43	43	0	3	0	0	111	8.00	
	NR2E3	2	2	0	0	2	2	0	0	0	0	8	0.58	
	NR2F1	3	3	6	11	17	17	4	2	1	0	64	4.61	
	NR2F6	3	2	0	18	2	2	0	0	0	0	27	1.95	
	NR3C1	0	2	2	17	3	3	0	1	0	0	28	2.02	
	NR3C2	1	7	2	12	5	5	1	0	2	0	35	2.52	
	NR4A2	4	0	1	5	13	13	2	0	0	0	38	2.74	
	NR4A3	2	3	1	19	6	6	2	1	0	0	40	2.88	
	NR5A2	4	4	1	25	2	2	1	2	0	0	41	2.96	
	ESRRA	4	1	0	18	2	2	0	1	1	0	29	2.09	
	ESRRB	0	1	0	13	5	5	0	1	0	0	25	1.80	
	ESRRG	2	3	2	19	7	7	2	2	0	0	44	3.17	
	NR6A1	1	5	0	22	7	7	0	0	0	0	42	3.03	
	RORA	1	5	0	5	2	2	1	0	0	0	16	1.15	
	RORB	1	3	0	18	1	1	0	0	1	0	25	1.80	
	RORC	8	9	1	28	6	6	0	0	0	0	58	4.18	
	ACTR1A	4	3	4	8	10	10	1	0	0	0	40	2.88	
	SF1	1	5	0	19	5	5	0	1	0	0	36	2.60	
STX8	1	3	3	9	17	17	0	2	0	0	52	3.75		

SUPPLEMENTARY TABLE 1: data from TCGA measuring the incidence of CNA or mutation of the 48 nuclear receptors (NR) in prostate cancer samples.